Positioning Systemic Therapy and Select Local Approaches in Desmoid Tumor

The therapeutic landscape for desmoid tumor has evolved considerably, with systemic therapy now playing a central role in the management of progressive or symptomatic disease. In this segment, the panel discusses how contemporary guidelines increasingly favor systemic treatment over routine local intervention, particularly for tumors in anatomically challenging locations or those associated with meaningful symptom burden.

Agents such as tyrosine kinase inhibitors and gamma secretase inhibitors have demonstrated clinically meaningful activity, including disease stabilization and symptomatic improvement. These options provide an alternative to surgery, particularly when resection would carry substantial morbidity or risk of recurrence. The panel emphasizes that systemic therapy decisions should be individualized based on tumor location, symptom severity, patient preference, and overall functional impact.

Local therapies, including radiation or ablative approaches, may still have a role in carefully selected patients. However, their use requires thoughtful consideration of long-term toxicity, potential complications, and institutional expertise. Rather than viewing systemic and local modalities as competing strategies, clinicians are encouraged to consider them within a broader, patient-centered framework.

Ultimately, the discussion reinforces that treatment selection in desmoid tumor is nuanced. Systemic therapy is often positioned as the preferred initial active intervention when observation is no longer appropriate, while local approaches may be reserved for specific circumstances. Aligning therapeutic choice with both disease biology and patient priorities remains central to contemporary desmoid tumor management.